BioRegenx, Inc.
BioRegenx, Inc.
Your view on BRGX
Overview
What the company does, where it operates, and who runs it.
About BioRegenx, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- William Resides
- Headquarters
- 7407 Ziegler Road, Chattanooga, TN, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- William Resides
- Headquarters
- 7407 Ziegler Road, Chattanooga, TN, US
BioRegenx, Inc. develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally.
The company offers Endocalyx Pro, a dietary supplement targeting microvascular capillary health and a range of other supplements under the MyBodyRx brand name; GlycoCheck software; and other health and wellness devices, such as pulsed electro-magnetic field devices, as well as StimaWELL and ReLounge, an electronic muscle stimulation therapy device; and markets hydrogen water products.
It also develops TruScan.Ai mobile app/website that integrates additional health indicators; and VitalWellness app, which merge its DNA and epigenetics platform. In addition, the company operates a social media content management platform, including its interactive search engine.
Further, it provides DocSun Artificial Intelligence (AI) Engine, which integrates advanced ballistocardiography that detects an individual's heartbeat without touch; photoplethysmography, a method that uses light to track the flow of blood; and distributes wellness devices.
The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioRegenx, Inc., and the rating behind it. BRGX last traded at $0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioRegenx, Inc.. Starting points for BioRegenx, Inc.: beta -2.85 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioRegenx, Inc.. BioRegenx, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioRegenx, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioRegenx, Inc.. BioRegenx, Inc. has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioRegenx, Inc. valued side by side against its closest peers. BioRegenx, Inc. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioRegenx, Inc., and how their positions are changing. At a $11.5M market value, institutional positions materially move BioRegenx, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioRegenx, Inc. executives and directors. Shares of BioRegenx, Inc. have traded between $0.0074 and $0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioRegenx, Inc.. BioRegenx, Inc. is a $11.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioRegenx, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioRegenx, Inc.. Coverage tracks BioRegenx, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.